ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing
- PMID: 35348673
- DOI: 10.1093/clinchem/hvac021
ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based Noninvasive Testing
Abstract
Background: ALK rearrangements are present in 5% of nonsmall cell lung cancer (NSCLC) tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using liquid biopsies, although challenging, can expand the therapeutic options for ALK-positive NSCLC patients considerably. RNA inside extracellular vesicles (EVs) is protected from RNases and other environmental factors, constituting a promising source for noninvasive fusion transcript detection.
Methods: EVs from H3122 and H2228 cell lines, harboring EML4-ALK variant 1 (E13; A20) and variant 3 (E6a/b; A20), respectively, were successfully isolated by sequential centrifugation of cell culture supernatants. EVs were also isolated from plasma samples of 16 ALK-positive NSCLC patients collected before treatment initiation.
Results: Purified EVs from cell cultures were characterized by transmission electron microscopy (TEM), nanoparticle tracking analysis (NTA), and flow cytometry. Western blot and confocal microscopy confirmed the expression of EV-specific markers as well as the expression of EML4-ALK-fusion proteins in EV fractions from H3122 and H2228 cell lines. In addition, RNA from EV fractions derived from cell culture was analyzed by digital PCR (dPCR) and ALK-fusion transcripts were clearly detected. Similarly, plasma-derived EVs were characterized by NTA, flow cytometry, and the ExoView platform, the last showing that EV-specific markers captured EV populations containing ALK-fusion protein. Finally, ALK fusions were identified in 50% (8/16) of plasma EV-enriched fractions by dPCR, confirming the presence of fusion transcripts in EV fractions.
Conclusions: ALK-fusion transcripts can be detected in EV-enriched fractions. These results set the stage for the development of EV-based noninvasive ALK testing.
Keywords: ALK-TKI; EML4-ALK; NSCLC; extracellular vesicles; liquid biopsy.
© American Association for Clinical Chemistry 2022.
Similar articles
-
Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.Mol Oncol. 2023 Sep;17(9):1884-1897. doi: 10.1002/1878-0261.13468. Epub 2023 Jun 6. Mol Oncol. 2023. PMID: 37243883 Free PMC article.
-
Exon array profiling detects EML4-ALK fusion in breast, colorectal, and non-small cell lung cancers.Mol Cancer Res. 2009 Sep;7(9):1466-76. doi: 10.1158/1541-7786.MCR-08-0522. Epub 2009 Sep 8. Mol Cancer Res. 2009. PMID: 19737969
-
Sensitive detection of EML4-ALK fusion oncoprotein of lung cancer by in situ proximity ligation assay.Clin Chem Lab Med. 2013 Sep;51(9):1843-8. doi: 10.1515/cclm-2013-0044. Clin Chem Lab Med. 2013. PMID: 23612660
-
Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.Lung Cancer. 2021 Aug;158:126-136. doi: 10.1016/j.lungcan.2021.06.012. Epub 2021 Jun 12. Lung Cancer. 2021. PMID: 34175504 Review.
-
Molecular findings reveal possible resistance mechanisms in a patient with ALK-rearranged lung cancer: a case report and literature review.ESMO Open. 2019 Oct 25;4(5):e000561. doi: 10.1136/esmoopen-2019-000561. eCollection 2019. ESMO Open. 2019. PMID: 31749991 Free PMC article. Review.
Cited by
-
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.Br J Cancer. 2024 Jan;130(1):63-72. doi: 10.1038/s41416-023-02491-9. Epub 2023 Nov 16. Br J Cancer. 2024. PMID: 37973956 Free PMC article.
-
Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non-small-cell lung cancer patients using RNA-based techniques.Mol Oncol. 2023 Sep;17(9):1884-1897. doi: 10.1002/1878-0261.13468. Epub 2023 Jun 6. Mol Oncol. 2023. PMID: 37243883 Free PMC article.
-
Liquid Biopsy in Lung Cancer: Biomarkers for the Management of Recurrence and Metastasis.Int J Mol Sci. 2023 May 17;24(10):8894. doi: 10.3390/ijms24108894. Int J Mol Sci. 2023. PMID: 37240238 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical